Asklepios, Baxter deal
Baxter will acquire Asklepios' Chatham Therapeutics LLC affiliate for $70 million up front. Chatham will also be eligible for undisclosed development, regulatory and sales milestones. Baxter declined to provide details.
In May 2012, Chatham granted Baxter exclusive, worldwide rights to develop and commercialize hemophilia B treatments using Chatham's Biological Nano Particles adeno-associated virus (AAV) vector therapy technology. Through the acquisition, Baxter will gain broader access to the technology, including a preclinical hemophilia A program and potential future application to additional hemophilia treatments. Chatham has exclusive rights from Asklepios under an April 2012 deal to use the gene therapy technology for hemophilia treatments (see BioCentury, June 11, 2012). ...